AbelZeta Inc. — Biomedical Watch V2

Traitements0programmes

Essais4liés

Publications0liées

SourceDBlocale

Traitements

0

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Aucun traitement.

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
C-CAR168	SEP	Phase 1	NCT07854483	C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy	NOT_YET_RECRUITING
C-CAR168	SEP	Phase 1/2	NCT06935474	C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease	WITHDRAWN
C-CAR168	SEP	Phase 1/2	NCT07825389	C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy	NOT_YET_RECRUITING
C-CAR168	SEP	Phase 2	NCT07729826	C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.